news
p53’s role in ulcerative colitis and its progression to cancer
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
List view / Grid view
ulcerative colitis (UC)
news
Damaged small intestine repaired with hPSC-derived organoids
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
news
Epigenetic dysregulation mechanism in Crohn’s disease discovered
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
news
New biological pathway in IBD discovered
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
news
Exploring the role of class IIa HDACs in inflammatory diseases
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
article
How 3D human tissue models are transforming drug discovery
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific…
article
Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.